CAS 827316-43-8

1H-Pyrazole-4-carboxylic acid, 3-iodo-, ethyl ester

Description:

1H-Pyrazole-4-carboxylic acid, 3-iodo-, ethyl ester is a chemical compound characterized by its pyrazole ring structure, which is a five-membered ring containing two adjacent nitrogen atoms. This compound features a carboxylic acid functional group and an ethyl ester moiety, contributing to its reactivity and solubility properties. The presence of the iodine atom at the 3-position of the pyrazole ring enhances its potential for various chemical reactions, including nucleophilic substitutions and coupling reactions. This compound is typically used in organic synthesis and may serve as an intermediate in the production of pharmaceuticals or agrochemicals. Its molecular structure allows for diverse applications in medicinal chemistry, particularly in the development of compounds with biological activity. Additionally, the compound's stability and solubility in organic solvents make it suitable for various laboratory applications. As with many chemical substances, proper handling and safety precautions are essential due to potential hazards associated with its use.

Formula: C₆H₇IN₂O₂

Ethyl 3-iodo-1H-pyrazole-4-carboxylate

CAS: 827316-43-8

Formula: C₆H₇IN₂O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 266.0365

Ref: IN-DA0058R0

Ethyl 3-iodo-1H-pyrazole-4-carboxylate

CAS: 827316-43-8

Ethyl 3-iodo-1H-pyrazole-4-carboxylate

Formula: C₆H₇IN₂O₂

Purity: 98%

Color and Shape: pale yellow solid

Molecular weight: 266.04g/mol

Ref: 54-OR307164

Ethyl 3-iodo-1H-pyrazole-4-carboxylate

CAS: 827316-43-8

Formula: C₆H₇IN₂O₂

Purity: 95%

Color and Shape: Solid

Molecular weight: 266.038

Ref: 10-F091531

3-Iodo-1H-pyrazole-4-carboxylic acid ethyl ester

CAS: 827316-43-8

Begaestat is a novel, orally active, small-molecule inhibitor of chymotrypsin-like activity in the human proteasome. It has been shown to be effective in inhibiting tumor cell growth and metastasis in animal models and has demonstrated clinical activity in phase I clinical trials. Begaestat inhibits the production of methylthioadenosine (MTA), which is an endogenous metabolite that can inhibit cancer cells. MTA inhibits the production of protein, leading to cell death by inhibiting protein synthesis and DNA replication. Begaestat also binds to a synthetic substrate that resembles the arginine site on the proteasome, thereby preventing the formation of an enzyme-substrate complex and inhibiting chymotrypsin-like activity.

Purity: Min. 95%

Ref: 3D-FI74684